By Dani Kass (January 28, 2022, 8:46 PM EST) — Attorneys on both sides of drug patent challenges at the Patent Trial and Appeal Board have to be extremely cautious to draft an obvious argument in a way that doesn’t undermine one for written description or enablement, according to an IPWatchdog panel.
While inter partes reviews involve only challenges based on obviousness — under Section 103 of the Patent Act — or anticipation, attorneys said arguments in the case have a high potential to hurt challenges in district courts or the U.S. International Trade Commission based on Section 112. The latter section deals with whether the patent’s specification sufficiently describes what…